SEC For	m 4																	
FORM 4 UNITED STAT					ES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549									OMB APPROVAL				
Section 16. Form 4 or Form 5 obligations may continue. See						T OF CHANGES IN BENEFICIAL OWNERSHIP									OMB Number: 3235-0287 Estimated average burden hours per response: 0.5			
1. Name and Address of Reporting Person [*] Horning Sandra								ker or Trading euticals, 1		(Ch	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (cive title Other (cree			ner				
	(Last) (First) (Middle) C/O OLEMA PHARMACEUTICALS, INC. 512 2ND STREET, 4TH FLOOR				3. Date of Earliest Transaction (Month/Day/Year) 11/18/2020								. Officer (give title Other (specify below) below)					
(Street) SAN FRANCISCO CA 94107				4.1	If Ame	ndment, I	Date	of Original File	ed (Month/Da	Line	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person							
(City)						tive Securities Acquired, Disposed of, or Beneficially								ally Owned				
1. Title of Security (Instr. 3) (Month/D				sactior	n 2 E ear) ii	A. Deemo Execution f any Month/Da	ed Date	, Transaction Disposed Code (Instr. 5)		ities Acquired (A) or d Of (D) (Instr. 3, 4 and		5. Amour Securitie Beneficia Owned F	nt of s ally ollowing	6. Own Form: (D) or I (I) (Inst	Direct o Indirect E tr. 4) C	7. Nature of Indirect Beneficial Ownership		
								Code V	Amount	(A) or (D)	Price	Price Reported Transaction (Instr. 3 and			(1	nstr. 4)		
		1	Fable II - Deriv (e.g.,					uired, Dis s, options,				Owned						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	ly I	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares							
Stock Option (Right to Buy)	\$19	11/18/2020		Α		86,083		(1)	11/17/2030	Common Stock	86,083	\$0.00	86,083	,	D			

Explanation of Responses:

1. The shares subject to the option vest in a series of 36 successive equal monthy installments measured from November 18, 2020, subject to the Reporting Person's continuous service through each applicable vesting date.

Remarks:

/s/ John B. Moriarty, Jr.,								
Attorney-in-Fact								

. .

11/19/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.